Anti-Jo-1 antibody positive polymyositis—successful therapy with leflunomide

References

• Dalakas MC. Autoimmune muscular pathologies. Neurol Sci 2005; 26(Suppl 1)S7–S8
   Google Scholar
• Oddis CV. Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies. Curr Rheumatol Rep 2005; 7: 87–93
   PubMedGoogle Scholar
• Buchbinder R, Hill CL. Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002; 4: 415–426
   PubMedGoogle Scholar
• Targoff IN. Update on myositis-specific and myositis-associated autoantibodies. Curr Opin Rheumatol 2000; 12: 475–481
   PubMed Web of Science ®Google Scholar
• Ranque-Francois B, Maisonobe T, Dion E, Piette JC, Chauveheid MP, Amoura Z, Papo T. Familial inflammatory inclusion body myositis. Ann Rheum Dis 2005; 64: 634–637
   PubMedGoogle Scholar
• Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 2005; 3: CD003643
   Google Scholar
• Cannon GW, Kremer JM. Leflunomide. Rheum Dis Clin North Am 2004; 30: 295–309
   PubMed Web of Science ®Google Scholar
• Poor G, Strand V. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: Multinational double-blind, randomized trial. Rheumatology (Oxford) 2004; 43: 744–749, Leflunomide Multinational Study Group.
   PubMed Web of Science ®Google Scholar
• Maddison P, Kiely P, Kirkham B, Lawson T, Moots R, Proudfoot D, et al. Leflunomide in rheumatoid arthritis: Recommendations through a process of consensus. Rheumatology (Oxford) 2005; 44: 280–286
   PubMed Web of Science ®Google Scholar
• Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: A pilot observational study. Lupus 2001; 10: 480–483
   PubMed Web of Science ®Google Scholar
• Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43: 315–320
   PubMed Web of Science ®Google Scholar
• Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, et al. Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 (leflunomide) in patients with advanced solid tumours. Clin Oncol 1999; 17: 1095–1104
   Google Scholar
• Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ. Polymyositis–dermatomyositis and malignant lesions: Does an association exist. Mayo Clin Proc 1986; 61: 645–653
   PubMed Web of Science ®Google Scholar
• Serratrice G, Schiano A, Pellissier JF, Pouget J. 135 cases of polymyositis. Rev Neurol 1986; 142: 906–917
   PubMedGoogle Scholar
• Lundberg, Chung Y-L. Treatment and investigation of idiopathic inflammatory myopathies. Rheumatol 2000; 39: 7–17
   PubMed Web of Science ®Google Scholar
• Laxer RM, Stein LD, Petty RE. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis. Arthritis Rheum 1987; 30: 328–334
   PubMed Web of Science ®Google Scholar
• Oddis CV, Medsger TA. Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis–dermatomyositis. J Rheumatol 1988; 15: 807–811
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52: 3570–3578
   PubMed Web of Science ®Google Scholar
• Metzger AL, Bohan A, Goldberg IS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy. Ann Intern Med 1974; 81: 182–189
   PubMed Web of Science ®Google Scholar
• Sokoloff MC, Goldberg LS, Pearson CM. Treatment of corticosteroid-resistant polymyositis with methotrexate. Lancet 1971; 1: 14–16
   PubMed Web of Science ®Google Scholar
• Bunch TW. Prednisone and azathioprine for polymyositis. Arthritis Rheum 1981; 24: 45–48
   PubMed Web of Science ®Google Scholar
• Mehregan DR, Su WPD. Cyclosporine treatment for dermatomyositis/polymyositis. Cutis 1993; 51: 59–61
   PubMed Web of Science ®Google Scholar
• Lueck CJ, Trend P, Swash M. Cyclosporin in the management of polymyositis and dermatomyositis. J Neurol Neurosurg Psychiatry 1991; 54: 1007–1008
   PubMedGoogle Scholar
• Sinoway PA, Callen JP. Chlorambucil: An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993; 36: 319–324
   PubMed Web of Science ®Google Scholar
• Bombardieri S, Hughes GRV, Neri R. Cyclophosphamide in severe polymyositis. Lancet 1988; 1: 1138–1139
   Google Scholar
• Kono DW, Klashman DJ, Gilbert RC. Successful IV pulse cyclophosphamide in refractory PM in three patients with SLE. J Rheumatol 1990; 17: 982–983
   PubMedGoogle Scholar
• Leroy JP, Drosos AA, Yiannopoulos DI, Youinou P, Moutsopoulos HM. Intravenous pulse cyclophosphamide therapy in myositis and Sjogren's syndrome. Arthritis Rheum 1990; 33: 1579–1581
   PubMedGoogle Scholar
• Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis. A randomised crossover study of two new cytotoxic regimens. Arthritis Rheum 1998; 41: 392–399
   PubMed Web of Science ®Google Scholar
• Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients. Am J Med 1991; 91: 162–168
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term follow-up of intravenous immunoglobulin infusions in chronic, refractory polymyositis. An open study with 35 adult patients. Arthritis Rheum 2002; 46: 467–474
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis and polymyositis. Neurology 1998; 51: 537–545
   Google Scholar
• Hachulla E. Dermatomyositis and polymyositis: Clinical aspects and treatment. Ann Med Interne (Paris) 2001; 152: 455–464
   PubMedGoogle Scholar
• Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity 2005; 38: 47–54
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Zampieri S, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-MI-2 antibodies. Autoimmunity 2005; 38: 79–83
   PubMed Web of Science ®Google Scholar
• Zampieri S, Ghirardello A, Iaccarino L, Tarricone E, Gambari PF, Doria A. Anti-JO-1 antibodies. Autoimmunity 2005; 38: 73–78
   PubMed Web of Science ®Google Scholar
• Spath M, Schroder M, Schlotter-Weigel B, Walter MC, Hautmann H, Leinsinger G, et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 2004; 251: 859–864
   PubMed Web of Science ®Google Scholar